Mono Pharmacare Ltd
Incorporated in 1994, Mono Pharmacare Limited is engaged in the business of marketing and distribution of pharmaceutical products[1]
- Market Cap ₹ 79.5 Cr.
- Current Price ₹ 45.0
- High / Low ₹ 75.0 / 28.1
- Stock P/E 84.6
- Book Value ₹ 15.6
- Dividend Yield 0.00 %
- ROCE %
- ROE %
- Face Value ₹ 10.0
Pros
Cons
- Stock is trading at 2.89 times its book value
- Company has high debtors of 241 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | |
|---|---|
| 33.09 | |
| 30.85 | |
| Operating Profit | 2.24 |
| OPM % | 6.77% |
| 0.06 | |
| Interest | 0.93 |
| Depreciation | 0.05 |
| Profit before tax | 1.32 |
| Tax % | 28.79% |
| 0.94 | |
| EPS in Rs | 0.76 |
| Dividend Payout % | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Sep 2023 | |
|---|---|---|
| Equity Capital | 12.37 | 17.67 |
| Reserves | 1.32 | 9.87 |
| 39.93 | 38.18 | |
| 8.96 | 9.56 | |
| Total Liabilities | 62.58 | 75.28 |
| 0.83 | 0.83 | |
| CWIP | 0.00 | 0.00 |
| Investments | 0.57 | 0.00 |
| 61.18 | 74.45 | |
| Total Assets | 62.58 | 75.28 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | |
|---|---|
| -39.54 | |
| -1.16 | |
| 40.73 | |
| Net Cash Flow | 0.04 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | |
|---|---|
| Debtor Days | 241.24 |
| Inventory Days | 408.21 |
| Days Payable | 86.66 |
| Cash Conversion Cycle | 562.78 |
| Working Capital Days | 570.61 |
| ROCE % |
Documents
Announcements
Annual reports
No data available.
Business segment
A) Marketing of Pharmaceutical Products[1]
Co. outsources manufacturing of most of its products and has 19 third-party manufacturers and sells all these products under its own Brand name - “DLS Export”.
Product Portfolio[1] Health Care products, Antibiotic medicines, Cough Cold Allergic medicines, Antifungal medicines, Nutraceutical medicines, Analgesic and antipyretic medicines, Antacid and antiemetics medicines, Cardiac - Diabetic medicines, and cosmocare products.